Please use this identifier to cite or link to this item:
https://ahro.austin.org.au/austinjspui/handle/1/32596| Title: | Radioembolization for hepatocellular carcinoma - Current evidence and patterns of utilization. | Austin Authors: | Briody, Hayley;Duong, David;Yeoh, Sern Wei;Hodgson, Russell;Yong, Tuck Leong;Hannah, Anthony;Lee, Michael J;Leong, Sum;Maingard, Julian;Asadi, Hamed ;Kok, Hong Kuan | Affiliation: | Interventional Radiology Service, Department of Radiology, Northern Health, Epping, Australia. Department of Gastroenterology and Hepatology, Northern Health, Epping, Australia. Department of Hepatopancreatobiliary Surgery, Northern Health, Epping, Australia. Department of Hepatopancreatobiliary Surgery, Northern Health, Epping, Australia. Department of Nuclear Medicine, Northern Health, Epping, Australia. Department of Radiology, Beaumont Hospital and Royal College of Surgeons in Ireland, Dublin, Ireland. Department of Vascular and Interventional Radiology, Singapore General Hospital, Singapore. Radiology Interventional Radiology Service, St Vincent's Hospital, Melbourne, Australia; Interventional Radiology Service, Monash Health, Melbourne, Australia. Interventional Radiology Service, Department of Radiology, Northern Health, Epping, Australia; Interventional Radiology Service, St Vincent's Hospital, Melbourne, Australia. |
Issue Date: | Jul-2023 | Date: | 2023 | Publication information: | Journal of Vascular and Interventional Radiology: JVIR 2023; 34(7) | Abstract: | Primary liver malignancy, of which hepatocellular carcinoma (HCC) is the most common type is the second most common cause of death from cancer worldwide. Given the historically poor prognosis of liver cancer, there has been major research into its treatment options with significant advancements over the last decade. Transarterial Radioembolization (TARE), is a locoregional treatment option for HCC that involves transarterial delivery of the β-emitter Yttrium-90 (90Y) via resin or glass microspheres to arterialised tumor vasculature, delivering a tumoricidal dose to the tumor. The recent 2022 update to the Barcelona Clinic Liver Cancer (BCLC) treatment algorithm has featured a more prominent role for locoregional treatment including the incorporation of radioembolization in very early (BCLC 0) and early stage (BCLC A) disease. This review will provide a contemporary summary for the evolving role of TARE in HCC treatment, in light of recent and upcoming trials. | URI: | https://ahro.austin.org.au/austinjspui/handle/1/32596 | DOI: | 10.1016/j.jvir.2023.03.020 | ORCID: | Journal: | Journal of Vascular and Interventional Radiology: JVIR | PubMed URL: | 37001638 | ISSN: | 1535-7732 | Type: | Journal Article | Subjects: | BCLC HCC Selective internal radiation therapy Yttrium-90 hepatocellular carcinoma radioembolization |
| Appears in Collections: | Journal articles |
Show full item record
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.